Bristol Myers Squibb Company $BMY Stock Bought by Monument Capital Management

09 Oct 2026, 11:29 by Michael Walen · The Markets Daily

Monument Capital Management grew its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 90.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 24,484 shares of the biopharmaceutical company’s stock after buying an additional 11,617 shares during the period. Monument Capital Management’s holdings in Bristol Myers Squibb were worth $1,528,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Primecap Management Co. CA purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $1,436,115,000. Legal & General Group Plc purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $980,862,000. BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp increased its stake in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Bristol Myers Squibb by 153.8% in the first quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company’s stock worth $540,393,000 after buying an additional 5,399,407 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Cantor Fitzgerald reduced their target price on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, Leerink Partners cut Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $73.00 to $59.00 in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average price target of $66.72.

Read Our Latest Research Report on BMY

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is currently owned by company insiders.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Zenbexus delivered a major Phase 3 win. Bristol Myers said the iberdomide combination with daratumumab and dexamethasone produced superior progression-free survival versus standard care in relapsed and refractory multiple myeloma, reducing the risk of disease progression or death by 51%. The result strengthens Zenbexus’s potential as a growth product and supports the company’s oncology strategy. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
Positive Sentiment: Growth products may offset older-drug declines. Reblozyl continues to post strong growth, while a Camzyos label expansion could broaden the addressable market. Investors also continue to highlight BMY’s dividend, value characteristics and potential for another earnings beat. Reblozyl Growth Outlook
Neutral Sentiment: Analysts expect a favorable earnings setup, citing Bristol Myers’ history of exceeding estimates and current earnings trends. However, these reports are projections rather than new company guidance. Bristol Myers Earnings Outlook
Neutral Sentiment: Market commentary remains divided. Some coverage favors BMY over Pfizer because of its specialized oncology portfolio, while other reports describe the pullback as a value opportunity supported by the dividend.
Negative Sentiment: Analyst actions are a near-term headwind. Cantor Fitzgerald cut its price target to $53 and assigned a neutral rating, while Morgan Stanley issued a sell recommendation. These calls reinforce concerns about competition, debt and dependence on newer products to replace declining legacy revenue. Morgan Stanley Sell Rating

Bristol Myers Squibb Stock Down 0.3%

NYSE:BMY opened at $59.51 on Friday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The company’s fifty day moving average price is $64.27 and its 200-day moving average price is $60.28. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The firm has a market capitalization of $121.57 billion, a P/E ratio of 13.11, a PEG ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the previous year, the firm posted $1.46 earnings per share. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.